AU Patent

AU2017251723A1 — 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment

Assigned to H Lundbeck AS · Expires 2017-11-09 · 9y expired

What this patent protects

1-[2-(2,4-DIMETHYLPHENYLSULFANYL)-PHENYL]PIPERAZINE AS A COMPOUND WITH COMBINED SEROTONIN REUPTAKE, 5-HT3 AND 5-HT1A ACTIVITY FOR THE TREATMENT OF COGNITIVE IMPAIRMENT 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine exhibits potent activity on SERT, 5-HT 3 and 5-HTlA and may a…

USPTO Abstract

1-[2-(2,4-DIMETHYLPHENYLSULFANYL)-PHENYL]PIPERAZINE AS A COMPOUND WITH COMBINED SEROTONIN REUPTAKE, 5-HT3 AND 5-HT1A ACTIVITY FOR THE TREATMENT OF COGNITIVE IMPAIRMENT 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine exhibits potent activity on SERT, 5-HT 3 and 5-HTlA and may as such be useful for the treatment of cognitive impairment, especially in depressed patients.

Drugs covered by this patent

Patent Metadata

Patent number
AU2017251723A1
Jurisdiction
AU
Classification
—
Expires
2017-11-09
Drug substance claim
No
Drug product claim
No
Assignee
H Lundbeck AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.